Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis
Conclusion: These data suggested that the prognosis of patients with LD-SCLC was improving. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
Conclusion. Considering the findings of this study, osimertinib appears to be an effective and safe treatment option for patients with poor PS and advanced NSCLC harboring sensitiveEGFR mutations. To obtain conclusive results, further studies with larger cohorts are warranted. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Conclusion. The RP2D of selinexor was 60 mg QW in combination with CT. The combination conferred viable clinical activity with durable objective responses which should further be explored in tumor types for which CT is used as standard of care.Trial information. ClinicalTrials.gov Identifier: NCT02419495. Sponsor(s): Karyopharm Therapeutics. (Trial registration: NCT02419495. Registered 14 April 2015,https://clinicaltrials.gov/ct2/show/NCT02419495). (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Conclusion. Patients who received atezolizumab plus bevacizumab as 1st-line therapy had better clinical outcome than those who received atezolizumab plus bevacizumab in later lines. The AFP response at 6 weeks could be a predictor of disease progression. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model
Conclusion MID-AC induces an efficient boron neutron capture reaction because the albumin contained in MID-AC is retained in the tumor and has a considerable potential to become an effective delivery system for BNCT in treating high-grade gliomas. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells
This study provides new insights into the STMN1 functions and microtubule dynamics in APL. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients
Conclusion. The PACOX regimen demonstrated good anti-cancer activity and survival advantage in advanced pre-treated HCC with favourable safety profile. It warrants further phase II/III studies. (Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
This study aimed to determine the genetic polymorphisms involved in the clinical response to preoperative DCF therapy in esophageal cancer patients.Methods. We included 56 patients with measurable lesions who received preoperative DCF therapy for esophageal cancer. Twenty-one genetic polymorphisms were analyzed, and univariate logistic regression analysis was used to evaluate the association between genetic polymorphisms and tumor shrinkage. A multivariate logistic regression analysis adjusted for T category and tumor location and a univariate analysis for potential genetic factors withP values < 0.05 were perform...
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Relapsing polychondritis after treatment with PD-1 blockade
SummaryNivolumab, a programmed death 1 blockade drug, is used in various types of cancers and can cause a unique immune-related adverse event (irAE). Relapsing polychondritis (RP) is a rare autoimmune disease that mainly involves inflammation of the auricle, nose and airway cartilage. A 72-year-old man with mandibular cancer received nivolumab after surgery for the primary lesion and radiation therapy for lung metastases. He then developed radiation pneumonitis, and prednisolone (PSL) was started. During the tapering of PSL, he developed exertional dyspnea and cough. The condition of mandibular cancer and radiation pneumon...
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
(Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non ‑small cell lung cancer
(Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma
(Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single ‑center, multi‑arm phase Ib study
(Source: Investigational New Drugs)
Source: Investigational New Drugs - April 1, 2022 Category: Drugs & Pharmacology Source Type: research
Acknowledgement of Reviewers 2021
(Source: Investigational New Drugs)
Source: Investigational New Drugs - March 30, 2022 Category: Drugs & Pharmacology Source Type: research
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy
In conclusion, our outcomes recommend the Pd(II) complex as a new optimistic candidate for tumor therapy after further studies for validation. (Source: Investigational New Drugs)
Source: Investigational New Drugs - March 30, 2022 Category: Drugs & Pharmacology Source Type: research
